Search Results

Cellphire Therapeutics, Inc. announced today the appointment of Pamela B. Conley , Ph.D. to the company’s Board of Directors.

Cellphire Therapeutics, Inc., announced today that the 1st patient has been treated in its Phase 2/3 clinical trial, Randomized Controlled Trial Comparing Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets to Liquid Stored Platelets in Patients Undergoing Cardiopulmonary Bypass Surgery (CRYPTICS).

Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately.

Cellphire Therapeutics, Inc., the global leader in long-term stabilization and storage of platelets, announced today the close of a $15 million Series A financing round led by Simcah Management.

Cellphire, the global leader in long-term stabilization and storage of platelets, is proud to announce that the Armed Services Blood Program (ASBP) has awarded Cellphire President G. Michael Fitzpatrick, PhD, with the 2020 ASBP Lifetime Achievement Award for his service and significant contributions to ASBP and the warfighter.

Cellphire, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its third contract option valued at $33.3 million to support Cellphire’s next generation platelet-based hemostatic product, Thrombosomes®, through a Phase 2 clinical trial in bleeding thrombocytopenic patients.

Under the contract, Cellphire will perform all research, development, manufacturing, and regulatory activities.

Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to start a Phase 2 clinical trial of Thrombosomes in bleeding patients with thrombocytopenia.

Cellphire, the global leader in long-term stabilization and storage of platelets, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS).

Intensity Therapeutics, Inc. announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024.